NCT06261502View on ClinicalTrials.gov

Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

May 1, 2025

Primary Completion Date

December 1, 2027

Study Completion Date

December 1, 2027

Conditions
Fragile X Syndrome
Interventions
DRUG

CBD Oral Solution

Participants will start with oral CBD dose of 5 mg/kg/day for two weeks and then increase to 10 mg/kg/day.

DRUG

Placebo

Participants will receive a dose of a placebo composed of the inactive ingredients of CBD of the same volume as the CBD Oral Solution.

Sponsors

Collaborators (1)

Jazz Pharmaceuticals
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Jazz Pharmaceuticals

INDUSTRY

collaborator

Centre de recherche du Centre hospitalier universitaire de Sherbrooke

OTHER

lead

Université de Sherbrooke

OTHER

NCT06261502 - Effect of CANnabidiol on Anxiety and GABAergic Function in Individuals with Fragile-X Syndrome | Biotech Hunter | Biotech Hunter